Stanford scientists designed a nanobody platform to inhibit the activity of granulysin, a protein that is often found in arterial plaque and released by T cells, to prevent the development of atherosclerosis such as heart attack and strokes.
Stanford researchers have designed a nanobody platform to selectively block a key region on T cells found within arterial plaque, with the aim of preventing thrombotic complications and myocarditis.
Researchers in Prof. Brian Feldman's laboratory have developed a patented drug screen to identify compounds that could potentially treat obesity and metabolic disease by converting cells to calorie-burning brown fat.